1-12 of 12
Robert J. Motzer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B022: Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens

Kelly N. Fitzgerald, Cihan Duzgol, Andrea Knezevic, Rachel Jacobi, Ritesh R. Kotecha, David H. Aggen, Maria I. Carlo, Neil J. Shah, Martin H. Voss, Darren R. Feldman, Robert J. Motzer, Chung-Han Lee
Journal: Cancer Research
Cancer Res (2023) 83 (16_Supplement): B022.
https://doi.org/10.1158/1538-7445.KIDNEY23-B022
Published: 15 August 2023
View articletitled, Abstract B022: Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens
Journal Articles

Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers

Daniel J. George, Jean-Francois Martini, Yen-Hwa Chang, Michael Staehler, Jan Breza, Jean-Jacques Patard, Robert J. Motzer, Ahmed Magheli, Bernard Escudier, Giacomo Carteni, Paola Gerletti, Sherry Li, Michelle Casey, Brigitte Laguerre, Hardev S. Pandha, Allan J. Pantuck, Anup Patel, Maria Lechuga, Alain Ravaud
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1771.
https://doi.org/10.1158/1538-7445.AM2017-1771
Published: 01 July 2017
View articletitled, Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers
Journal Articles

Abstract 52: Identification of genomic alterations associated with metastasis in clear cell renal cell carcinoma

Venkata J. Thodima, Banumathy Gowrishankar, Ana Molina, Murielle Georges, RSK Chaganti, Robert J. Motzer, Jane Houldsworth
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 52.
https://doi.org/10.1158/1538-7445.AM2014-52
Published: 01 October 2014
View articletitled, Abstract 52: Identification of genomic alterations associated with metastasis in clear cell renal cell carcinoma
Journal Articles

Abstract 3515: Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers.

Martin H. Voss, A Ari Hakimi, Can G. Pham, A Rose Brannon, Ying-Bei Chen, Luis F. Cunha, Oguz Akin, Han Liu, Shugaku Takeda, Sasinya N. Scott, Nicholas D. Socci, Agnes Viale, Nikolaus Schultz, Chris Sander, Victor E. Reuter, Paul Russo, Emily H. Cheng, Robert J. Motzer, Michael F. Berger, James J. Hsieh
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3515.
https://doi.org/10.1158/1538-7445.AM2013-3515
Published: 15 April 2013
View articletitled, Abstract 3515: Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers.
Journal Articles

Abstract 765: Growth rates of tumors with numerous histologies remain constant while patients are on therapy

Wilfred D. Stein, Julia Wilkerson, Bamidele Adesunloye, Ravi Madan, Susan E. Bates, Samuel Wells, William Dahut, Yang-min Ning, Sen Hong Zhuang, Robert J. Motzer, Tito Fojo
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 765.
https://doi.org/10.1158/1538-7445.AM2012-765
Published: 15 April 2012
View articletitled, Abstract 765: Growth rates of tumors with numerous histologies remain constant while patients are on therapy
Journal Articles

Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression

Miguel A. López-Lago, Venkata J. Thodima, Asha Guttapalli, Timothy Chan, Adriana Heguy, Ana M. Molina, Victor E. Reuter, Robert J. Motzer, Raju S. K. Chaganti
Journal: Cancer Research
Cancer Res (2010) 70 (23): 9682–9692.
https://doi.org/10.1158/0008-5472.CAN-10-2279
Published: 06 December 2010
View articletitled, Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression
Open the PDF for Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression in another window
Includes: Supplementary data
Journal Articles

Soluble protein biomarkers of pharmacodynamic activity of the multi-targeted kinase inhibitor SU11248 in patients with metastatic renal cell cancer.

Samuel E. Deprimo, Carlo L. Bello, John Smeraglia, David R. Shalinsky, James Freddo, Charles M. Baum, Brian I. Rini, Dror Michaelson, Robert J. Motzer, Dominic G. Spinella
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 108.
Published: 01 May 2005
View articletitled, Soluble protein biomarkers of pharmacodynamic activity of the multi-targeted kinase inhibitor SU11248 in patients with metastatic renal cell cancer.
Journal Articles

Chromosomal Amplification Is Associated with Cisplatin Resistance of Human Male Germ Cell Tumors

Pulivarthi H. Rao, Jane Houldsworth, Nallasivam Palanisamy, V. V. V. S. Murty, Victor E. Reuter, Robert J. Motzer, George J. Bosl, R. S. K. Chaganti
Journal: Cancer Research
Cancer Res (1998) 58 (19): 4260–4263.
Published: 01 October 1998
View articletitled, Chromosomal Amplification Is Associated with Cisplatin Resistance of Human Male Germ Cell Tumors
Open the PDF for Chromosomal Amplification Is Associated with Cisplatin Resistance of Human Male Germ Cell Tumors in another window
Journal Articles

Phase I Trial with Pharmacokinetic Analyses of High-Dose Carboplatin, Etoposide, and Cyclophosphamide with Autologous Bone Marrow Transplantation in Patients with Refractory Germ Cell Tumors

Robert J. Motzer, Subhash C. Gulati, William P. Tong, Celia Menendez-Botet, Peter Lyn, Madhu Mazumdar, Vaia Vlamis, S. Lin, George J. Bosl
Journal: Cancer Research
Cancer Res (1993) 53 (16): 3730–3735.
Published: 01 August 1993
View articletitled, Phase I Trial with Pharmacokinetic Analyses of High-Dose Carboplatin, Etoposide, and Cyclophosphamide with Autologous Bone Marrow Transplantation in Patients with Refractory Germ Cell Tumors
Open the PDF for Phase I Trial with Pharmacokinetic Analyses of High-Dose Carboplatin, Etoposide, and Cyclophosphamide with Autologous Bone Marrow Transplantation in Patients with Refractory Germ Cell Tumors in another window
Journal Articles

Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression

Robert J. Motzer, David M. Nanus, Paul O'Moore, Howard I. Scher, Dean F. Bajorin, Victor Reuter, William P. Tong, Jacqueline Iversen, Carl Louison, Anthony P. Albino, George J. Bosl
Journal: Cancer Research
Cancer Res (1992) 52 (20): 5775–5779.
Published: 01 October 1992
View articletitled, Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression
Open the PDF for Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression in another window
Journal Articles

Multiple Biological Markers in Germ Cell Tumor Patients Treated with Platinum-based Chemotherapy

Frederica P. Perera, Robert J. Motzer, Deliang Tang, Eddie Reed, Riccardo Parker, Dorothy Warburton, Patrick O'Neill, Richard Albertini, William L. Bigbee, Ronald H. Jensen, Regina Santella, Wei-Yann Tsai, Gabriella Simon-Cereijido, Colleen Randall, George Bosl
Journal: Cancer Research
Cancer Res (1992) 52 (13): 3558–3565.
Published: 01 July 1992
View articletitled, Multiple Biological Markers in Germ Cell Tumor Patients Treated with Platinum-based Chemotherapy
Open the PDF for Multiple Biological Markers in Germ Cell Tumor Patients Treated with Platinum-based Chemotherapy in another window
Journal Articles

Blood Group-related Antigens in Human Germ Cell Tumors

Robert J. Motzer, Victor E. Reuter, Carlos Cordon-Cardo, George J. Bosl
Journal: Cancer Research
Cancer Res (1988) 48 (18): 5342–5347.
Published: 01 September 1988
View articletitled, Blood Group-related Antigens in Human Germ Cell Tumors
Open the PDF for Blood Group-related Antigens in Human Germ Cell Tumors in another window